Andreas Roos
Adjunct Professor, University of Ottawa
Scientific Officer, Department of Neuropediatrics, University Hospital Essen
Email AndreasAndreas completed his PhD in 2009 with Professor Jan Senderek in the Neurogenetics group of the Institute of Human Genetics of RWTH-Aachen University in Germany, where his thesis focused on the elucidation of molecular and biochemical mechanisms in autosomal recessive Charcot-Marie-Tooth neuropathies. Following a postdoc in the Institute of Molecular Biology and Medical Biochemistry at the University of Saarland, he became a junior group leader at the Institute of Neuropathology at RWTH-Aachen University. Subsequently, he took on the role of group lead of the Tissue Omics group at the Leibniz Institute of Analytical Science (ISAS) in Dortmund, focusing on applied proteomics toward a better understanding of the molecular genesis of neuromuscular diseases. In 2015 he moved to Newcastle upon Tyne (UK) as Scientific Officer in the John Walton Muscular Dystrophy Research Centre under Professor Hanns Lochmüller. After moving to Essen in Germany in 2018 to become Scientific Officer in the University Hospital Essen’s Department of Neuropediatrics, together with Prof. Ulrike Schara he was awarded a 2.9M Euro grant from the European Regional Development Fund for NMD-GPS, a major interdisciplinary multi-omics project aiming to improve the diagnostic management of patients with neuromuscular diseases as well as to group these diseases according to their underlying pathomechanisms.
In 2019 Andreas was awarded an adjunct professorship at the University of Ottawa, where he will be an external/visiting member of the Lochmüller Lab team, teaching applied proteomics in the context of neuromuscular diseases, co-supervising students and continuing his many close scientific collaborations with the group.
In 2023, Andreas received the World Muscle Society’s President’s Prize for Emerging Myologist of the Year.
![Dr. Andreas Roos Dr. Andreas Roos](https://lochmullerlab.org/files/Andreas-Roos.jpg)
Read more about Andreas
Recent publications
Chiu, C, Küchler, A, Depienne, C, Preuße, C, Marina, AD, Reis, A et al.. Skeletal muscle vulnerability in a child with Pitt-Hopkins syndrome. Skelet Muscle. 2024.14 (1)15 PMID:39026379
Bertino, F, Mukherjee, D, Bonora, M, Bagowski, C, Nardelli, J, Metani, L et al.. Dysregulation of FLVCR1a-dependent mitochondrial calcium handling in neural progenitors causes congenital hydrocephalus. Cell Rep Med. 2024.5 (7)101647 PMID:39019006
Holzer, MT, Uruha, A, Roos, A, Hentschel, A, Schänzer, A, Weis, J et al.. Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy. Acta Neuropathol. 2024.148 (1)6 PMID:39012547
Nelke, C, Schroeter, CB, Barman, S, Stascheit, F, Masanneck, L, Theissen, L et al.. Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering. EBioMedicine. 2024.105 105231 PMID:38959848
Schroeter, CB, Nelke, C, Stascheit, F, Huntemann, N, Preusse, C, Dobelmann, V et al.. Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis. Acta Neuropathol. 2024.147 (1)102 PMID:38888758
Forsting, J, Rohm, M, Froeling, M, Güttsches, AK, Südkamp, N, Roos, A et al.. Author Correction: Quantitative muscle MRI captures early muscle degeneration in calpainopathy. Sci Rep. 2024.14 (1)10381 PMID:38710928
Athamneh, M, Daya, N, Hentschel, A, Gangfuss, A, Ruck, T, Marina, AD et al.. Proteomic studies in VWA1-related neuromyopathy allowed new pathophysiological insights and the definition of blood biomarkers. J Cell Mol Med. 2024.28 (8)e18122 PMID:38652110
Distelmaier, F, Sezer, A, Helm, C, Waldmüller, S, Seibt, A, Gangfuß, A et al.. Biallelic truncating variants in PACSIN3 cause childhood-onset myopathy with hyperCKaemia. Brain. 2024.147 (7)e45-e49 PMID:38637313
Della Marina, A, Hentschel, A, Czech, A, Schara-Schmidt, U, Preusse, C, Laner, A et al.. Novel Genetic and Biochemical Insights into the Spectrum of NEFL-Associated Phenotypes. J Neuromuscul Dis. 2024.11 (3)625-645 PMID:38578900
Roos, A, Schmitt, LI, Hansmann, C, Hezel, S, Salmanian, S, Hentschel, A et al.. Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy. Acta Neuropathol. 2024.147 (1)53 PMID:38470509
Smeets, H, Verbrugge, B, Bulbena, X, Hristova, L, Vogt, J, van Beckhoven, I et al.. European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17-19, 2023, Barcelona, Spain. Neuromuscul Disord. 2024.36 16-22 PMID:38306718
Kleefeld, F, Horvath, R, Pinal-Fernandez, I, Mammen, AL, Casal-Dominguez, M, Hathazi, D et al.. Multi-level profiling unravels mitochondrial dysfunction in myotonic dystrophy type 2. Acta Neuropathol. 2024.147 (1)19 PMID:38240888
See more on PubMed